Mission

At the forefront of medical innovation, Millennia Biopharma, Inc. is spearheading a revolution in early heart disease detection for women. Our groundbreaking Mycor® technology represents a quantum leap in diagnostic capabilities, combining the power of Next Generation Sequencing with cutting-edge AI language programming.

Mycor® isn't just an improvement—it's a paradigm shift. With an astounding 99% accuracy in detecting ischemia, it far outpaces the current standard-of-care diagnostics, setting a new gold standard in the industry. This leap from 74% to 99% accuracy isn't just a statistic; it's a lifeline for countless women at risk of heart disease.

What sets Mycor® apart is its ability to deliver absolute, value-based results through innovative liquid biopsy. Gone are the days of relying solely on symptoms and risk factors for probabilistic diagnoses. Mycor® provides clear, definitive answers, enabling not just the diagnosis of ischemic heart disease but also the precise monitoring of its progression.